$4.35
1.58% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Xeris Pharmaceuticals Inc Stock price

$4.35
-0.55 11.22% 1M
+1.07 32.62% 6M
+0.96 28.32% YTD
+2.13 95.95% 1Y
-0.16 3.55% 5Y
-15.87 78.49% 10Y
-15.87 78.49% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.07 1.58%
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Key metrics

Market capitalization $696.67m
Enterprise Value $867.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.90
P/S ratio (TTM) P/S ratio 3.13
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 29.87%
Revenue (TTM) Revenue $222.55m
EBIT (operating result TTM) EBIT $-22.49m
Free Cash Flow (TTM) Free Cash Flow $-27.43m
Cash position $58.44m
EPS (TTM) EPS $-0.30
P/E forward negative
P/S forward 2.60
EV/Sales forward 3.23
Short interest 11.43%
Show more

Is Xeris Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Xeris Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

Buy
83%
Hold
17%

Financial data from Xeris Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
223 223
30% 30%
100%
- Direct Costs 40 40
35% 35%
18%
183 183
29% 29%
82%
- Selling and Administrative Expenses 169 169
12% 12%
76%
- Research and Development Expense 25 25
1% 1%
11%
-12 -12
66% 66%
-5%
- Depreciation and Amortization 11 11
0% 0%
5%
EBIT (Operating Income) EBIT -22 -22
50% 50%
-10%
Net Profit -45 -45
30% 30%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Xeris Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xeris Pharmaceuticals Inc Stock News

Neutral
Business Wire
11 days ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. “We have built a strong foundation thro...
Neutral
Business Wire
25 days ago
CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.
Neutral
Seeking Alpha
about one month ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for a...
More Xeris Pharmaceuticals Inc News

Company Profile

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.

Head office United States
CEO John Shannon
Employees 377
Founded 2005
Website www.xerispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today